Financial Performance - For the fiscal year 2024, Republic Healthcare Limited reported revenue of approximately SGD 8.7 million, a decrease of about 13% from SGD 10.0 million in fiscal year 2023[12]. - The company recorded a loss of approximately SGD 0.20 million for the fiscal year 2024, compared to a loss of SGD 0.86 million in fiscal year 2023[12]. - The group's total revenue for the fiscal year 2024 was approximately SGD 8.7 million, a decrease of about SGD 1.3 million or 13% compared to SGD 10.0 million in fiscal year 2023[22]. - The total comprehensive loss for the year was approximately SGD 201,000, a decrease from SGD 862,000 in the fiscal year 2023[38]. - The net cash from operating activities was approximately SGD 0.1 million, compared to a net cash outflow of SGD 0.9 million in the fiscal year 2023[45]. - The group had cash and bank balances of approximately SGD 11.4 million as of December 31, 2024, down from SGD 11.9 million in the fiscal year 2023[45]. - The capital debt ratio at year-end was approximately 6%, a decrease from 7.6% in the fiscal year 2023[45]. - The employee costs for the year were approximately SGD 4.2 million, down from SGD 4.4 million in the fiscal year 2023[53]. - The group recorded a tax credit of approximately SGD 5,391 for the current year, compared to a tax expense of SGD 26,888 in fiscal year 2023[36]. - The company reported no dividend payment for the current fiscal year, consistent with the previous year[96]. Revenue Sources - Revenue from consultation services, medical examination services, and treatment services were approximately SGD 1,235,226 (14.2%), SGD 2,096,982 (24.2%), and SGD 5,324,389 (61.5%) respectively, contributing to the total revenue[24]. - The decrease in revenue was primarily due to increased competition in the primary healthcare sector and rising costs in core areas such as sexual health, men's health, and women's health[12]. Operational Challenges - Due to intense competition in the e-commerce market, the online healthcare business faced challenges, leading the company to pause its online expansion to refine strategies and improve backend systems[12]. - The group anticipates ongoing pressure from global economic uncertainty leading to increased operating costs and intensified competition from online healthcare service providers[19]. - Geopolitical tensions and ongoing inflation pressures are expected to increase operational costs for the company[14]. - The group expects to face challenges from both intensified competition in primary healthcare and overall economic pressures affecting profitability and inflation-related cost increases[23]. Strategic Initiatives - The company aims to enhance efficiency, optimize costs, and solidify its market position to drive sustainable growth despite industry challenges[13]. - The company made progress in expanding its education business, successfully establishing a presence in the Philippines, with plans to launch operations in the third quarter of 2025[12]. - The group aims to focus on cost optimization, operational efficiency, and strategic growth measures to navigate challenges and promote long-term sustainable development[21]. Employee and Staffing - The number of employees (including part-time staff) decreased from 37 in fiscal year 2023 to 34 in fiscal year 2024[30]. - Employee benefit expenses slightly decreased to approximately SGD 4.2 million in the current year[29]. - The company is actively monitoring labor market changes to adjust compensation plans for retaining talented employees[66]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and regularly reviews its practices[152]. - The board consists of more than 50% independent non-executive directors, ensuring a balanced composition for effective independent judgment[179]. - The company has established three board committees: the audit committee, nomination committee, and remuneration committee, to oversee specific aspects of the company's affairs[192]. - The audit committee includes three independent non-executive directors, with Mr. Yang serving as the chairman, ensuring independence and objectivity in financial reporting[194]. - The board of directors confirmed compliance with the GEM listing rules regarding securities trading standards[107]. Shareholder Information - As of December 31, 2024, Dr. Chen holds 350,000,000 shares, representing 56.09% of the company's issued shares of 624,000,000[140]. - Cher Sen Holdings Limited, wholly owned by Dr. Chen, holds the same number of shares, indicating a significant ownership concentration[141]. - The company confirms compliance with GEM listing rules, maintaining a public float of at least 25% of its issued shares[154]. Future Outlook - The company remains optimistic about the continued growth and reputation of the healthcare industry in Singapore despite increasing competition[14]. - The company has allocated SGD 222,000 for the establishment of a new healthcare-related education business, with ongoing efforts in this area[72]. - The remaining unutilized proceeds are expected to be used for operational funding, with a focus on adapting to changing market conditions[67][69].

[Clarification of Matters](index=1&type=section&id=Clarification) Clarifies a classification error in interim results concerning a financial asset, which did not impact total or net assets - The core of this clarification is the reclassification of **S$1,994,217** from 'Other financial assets at amortised cost' to 'Cash and cash equivalents'[1](index=1&type=chunk) [Corrected Unaudited Condensed Consolidated Statement of Financial Position](index=2&type=section&id=Unaudited%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) Provides the corrected financial position statement as of June 30, 2024, reclassifying a financial asset to cash and cash equivalents Summary of Corrected Financial Position Statement (As of June 30, 2024) | Item | June 30, 2024 (Unaudited) (S$) | December 31, 2023 (Audited) (S$) | | :--- | :--- | :--- | | **Total Assets** | **14,937,418** | **15,642,934** | |    Non-current assets total | 1,345,024 | 2,079,786 | |    Current assets total | 13,592,394 | 13,563,148 | |       *Other financial assets at amortised cost* | *–* | *–* | |       *Cash and cash equivalents* | *12,140,073* | *11,934,070* | | **Total Liabilities** | **2,341,961** | **2,891,420** | | **Net Assets** | **12,595,457** | **12,751,514** | | **Equity attributable to owners of the Company** | **12,595,457** | **12,751,514** | - All other information and content in the original interim results announcement remain unchanged, except for the disclosed adjustments[3](index=3&type=chunk) [Other Information and Directors' Statement](index=3&type=section&id=Other%20Information) Contains Board of Directors' signatures, director list, and standard disclaimers and compliance statements under HKEX Listing Rules - The announcement is issued by Chairman and Executive Director **Chan Chee Siang** on behalf of the Board[4](index=4&type=chunk) - The company's directors collectively and individually assume full responsibility for the accuracy and completeness of this announcement[5](index=5&type=chunk)

Financial Performance - Republic Healthcare Limited reported revenue of approximately SGD 4.5 million for the six months ended June 30, 2024, a decrease of about 16.7% compared to SGD 5.4 million in the same period last year[5]. - The gross profit for the period was approximately SGD 3.1 million, down about 11.4% from SGD 3.5 million in the previous year[5]. - Revenue for the six months ended June 30, 2024, decreased to SGD 4.48 million from SGD 5.40 million in the same period last year, representing a decline of approximately 17%[7]. - Total revenue for the six months ended June 30, 2024, was SGD 4,481,738, a decrease of 17% from SGD 5,403,458 for the same period in 2023[30]. - Treatment services revenue decreased to SGD 2,763,858, down 11.7% from SGD 3,128,131 in the previous year[30]. - Medical examination services revenue fell to SGD 1,074,389, a decline of 19.3% from SGD 1,331,375 in the prior year[30]. - The company reported a loss attributable to owners of SGD (156,057) for the six months ended June 30, 2024, compared to a loss of SGD (260,321) in the same period of 2023[34]. - The company recorded a net loss of SGD 0.15 million for the current period, an improvement from a net loss of SGD 0.28 million in the previous year, attributed to enhanced cost control measures[6]. - Basic loss per share for the six months ended June 30, 2024, was SGD (0.03), an improvement from SGD (0.04) in the previous year[34]. Operational Challenges - The decline in medical business sales was approximately 12%, significantly impacted by the closure of a treatment center, which affected overall revenue and patient volume[5]. - Increased competition from both new entrants and established companies has intensified, with competitors ramping up marketing efforts and launching new services[5]. - Economic factors have influenced patient spending patterns, with rising living costs leading patients to seek more affordable healthcare options[5]. - Recent revisions to healthcare regulations have resulted in increased operational costs and tighter compliance requirements, impacting revenue[5]. - A shift towards telemedicine and online consultation services has occurred, which typically have lower profit margins compared to in-person consultations[5]. Financial Position - Non-current assets as of June 30, 2024, totaled SGD 1.35 million, down from SGD 2.08 million as of December 31, 2023[8]. - Current assets increased slightly to SGD 13.59 million from SGD 13.56 million as of December 31, 2023[8]. - Total liabilities decreased to SGD 2.34 million from SGD 2.89 million as of December 31, 2023[9]. - The total cash and cash equivalents decreased by SGD 1,788,214 for the six months ended June 30, 2024, compared to an increase of SGD 700,821 in the same period of 2023[11]. - The cash and cash equivalents at the beginning of the period were SGD 11,934,070, while at the end of the period, they were SGD 10,145,856[11]. - Trade receivables as of June 30, 2024, amount to SGD 140,360, an increase from SGD 65,251 as of December 31, 2023[43]. - Trade payables as of June 30, 2024, total SGD 247,420, a decrease from SGD 334,759 as of December 31, 2023[50]. - The total carrying amount of property, plant, and equipment as of June 30, 2024, was SGD 1,904,887[36]. Strategic Initiatives - The company aims to expand its network of treatment centers and diversify its service offerings in high-potential areas to meet increasing comprehensive care demands[62]. - Investment in telemedicine platforms, electronic health records, and advanced diagnostic tools is crucial for improving patient care and operational efficiency[62]. - The strategy to expand healthcare education services is seen as a key growth area, with tailored training programs aimed at addressing industry skill gaps[63]. - The company anticipates that its healthcare education initiatives will contribute revenue in the third quarter of 2024, aligning with optimistic expectations for the sector[64]. - The online healthcare business platform "Quinn" has been launched, with ongoing improvements to user interface and experience[83]. Governance and Compliance - The financial statements have been prepared in accordance with International Financial Reporting Standards and applicable GEM listing rules, ensuring consistency with the previous audited financial statements[13]. - The company adopted all applicable new or revised International Financial Reporting Standards effective from January 1, 2023, with no significant impact on accounting policies or reported amounts[13]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and found them compliant with applicable accounting standards[100]. - The company has adopted a code of conduct for securities trading that complies with GEM Listing Rules, confirming full compliance by all directors during the reporting period[90]. Shareholder Information - As of June 30, 2024, Dr. Chen holds 350,000,000 shares, representing 56.09% of the company's issued share capital of 624,000,000 shares[93]. - Cher Sen Holdings Limited, wholly owned by Dr. Chen, holds 100% of its shares, indicating Dr. Chen's beneficial ownership[95]. - The total number of issued shares as of June 30, 2024, is 624,000,000[96]. - The company has not granted or agreed to grant any options under the share option scheme since its adoption, and there are no unexercised options as of June 30, 2024[93].

Financial Performance - The company recorded total revenue of approximately SGD 10 million for the fiscal year ending December 31, 2023, representing an increase of about 11.11% compared to SGD 9 million in the previous fiscal year[12]. - The company incurred a loss of approximately SGD 0.86 million in 2023, an improvement from a loss of SGD 1.5 million in 2022[12]. - Total revenue for the fiscal year 2023 was approximately SGD 10,002,000, an increase from SGD 9,040,000 in 2022, representing a growth of 10.7%[22]. - The overall comprehensive loss for the fiscal year 2023 was approximately SGD 862,000, a reduction from a loss of SGD 1,492,000 in 2022, indicating an improvement of 42.1%[35]. Revenue Breakdown - Revenue from consultation services, medical examination services, and treatment services amounted to approximately SGD 1.38 million, SGD 2.61 million, and SGD 6.02 million, respectively, accounting for about 13.8%, 26.0%, and 60.2% of total revenue[18]. - Revenue from medical examinations significantly increased by approximately SGD 639,000, contributing to a total of SGD 2,606,000, which is 26.0% of total revenue in 2023 compared to 21.7% in 2022[22]. Operational Challenges - The company faced challenges in its new business areas, particularly in telemedicine and education, with delays in launching an online portal due to necessary backend software improvements[12]. - Increased operational costs due to inflation, including labor and rental expenses, are anticipated to pressure the company's profitability[19]. - Global inflation and geopolitical tensions are expected to create uncertainty in the economic outlook, impacting operational costs for the company[13]. Future Plans - The company plans to restart the online portal in late 2024 after completing the acquisition of a newly established education company in February 2024[12]. - The company plans to establish a new online business branch for Dtap, with an estimated launch around May 2024[64]. - The company plans to utilize the remaining net proceeds for future expansion of existing businesses and potential acquisitions when suitable opportunities arise[65]. Financial Position - Cash and cash equivalents amounted to approximately SGD 11.9 million as of December 31, 2023, compared to SGD 10.8 million in 2022, indicating a strong liquidity position[40]. - The total equity as of December 31, 2023, was approximately SGD 12.8 million, down from SGD 13.6 million in 2022[40]. - The capital debt ratio as of December 31, 2023, was approximately 7.6%, an increase from 5.7% in 2022, reflecting a slight increase in leverage[40]. Employee and Operational Costs - Employee benefits expenses slightly decreased to approximately SGD 4.4 million in 2023 from the previous year, attributed to the closure of treatment centers and sale of two entities[27]. - Other operating expenses increased by 24.8% to approximately SGD 2.57 million in 2023, primarily due to higher-than-expected marketing expenses[31]. - The total employee count as of December 31, 2023, was 37, down from 39 in the fiscal year 2022, with employee costs remaining stable at approximately SGD 4.4 million[49]. Investments and Acquisitions - The company has allocated SGD 2,031,000 for the renovation and acquisition of fixed assets for a new DTAP treatment center in Jurong[67]. - The company has spent SGD 1,220,000 for the renovation and acquisition of fixed assets for a new SA treatment center in Jurong as of December 31, 2023[67]. - The company has invested approximately SGD 222,000 to establish a new healthcare-related education business as of December 31, 2023[69]. Governance and Compliance - The company has adopted corporate governance practices in accordance with the GEM Listing Rules, ensuring accountability and transparency[151]. - The board of directors consists of four members, with independent non-executive directors accounting for over 50%[156]. - The company has confirmed compliance with the non-competition agreement by all controlled persons for the current year[123]. Risk Management - The group has identified key risks including reliance on skilled professionals and potential impacts from regulatory changes[53][56]. - The company has implemented policies and procedures for risk management and internal controls, with the board responsible for monitoring their effectiveness[193]. - The Audit Committee is responsible for reviewing the effectiveness of the Group's risk management and internal control systems[170]. Shareholder Information - The company reported no dividends for the fiscal year 2023, consistent with the previous year[90]. - As of December 31, 2023, Dr. Chen held 350 million shares, representing 56.09% of the company's issued shares[130]. - The company confirms it maintains sufficient public float, with at least 25% of issued shares held by the public as of the report date[138].

Financial Performance - The group recorded revenue of approximately SGD 10 million for the fiscal year ending December 31, 2023, an increase of about 11.11% compared to SGD 9 million for the fiscal year 2022[14]. - The group incurred a loss of approximately SGD 0.86 million in 2023, an improvement from a loss of SGD 1.5 million in 2022[14]. - The group's total revenue for the year ended December 31, 2023, was approximately SGD 10.0 million, an increase of about SGD 1.0 million or 11.11% compared to SGD 9.0 million in the fiscal year 2022[22]. - Revenue from medical examination services increased significantly by approximately SGD 639,000, while treatment and consultation services saw slight increases[24]. - The revenue breakdown for 2023 included consultation services at SGD 1,379,000 (13.8%), medical examination services at SGD 2,606,000 (26.0%), and treatment services at SGD 6,017,000 (60.2%) of total revenue[24]. - The total comprehensive loss for the year was approximately SGD 862,000, a decrease from a total comprehensive loss of approximately SGD 1,492,000 in the fiscal year 2022[37]. - Employee benefits expenses slightly decreased to approximately SGD 4.4 million due to the closure of consultation centers and the sale of two physical locations[29]. - The group recorded an income tax expense of approximately SGD 26,888 in the current year, compared to an income tax credit of SGD 28,471 in the fiscal year 2022[36]. - The group has decided not to declare a final dividend for the year, consistent with the previous fiscal year[39]. - The group had cash and bank balances of approximately SGD 11.9 million as of December 31, 2023, compared to SGD 10.8 million in the fiscal year 2022[42]. - The net current assets of the group were approximately SGD 11.2 million as of December 31, 2023, down from SGD 12 million in the fiscal year 2022[42]. - The capital debt ratio as of December 31, 2023, was approximately 7.6%, an increase from 5.7% in the fiscal year 2022[42]. - The net cash generated from operating activities was approximately SGD 0.9 million for the fiscal year 2023, compared to a net cash used of SGD 0.7 million in the fiscal year 2022[42]. - The group recorded a foreign exchange gain of approximately SGD 117,000 due to the depreciation of the Hong Kong dollar against the Singapore dollar, compared to a loss of SGD 23,000 in the fiscal year 2022[45]. Operational Changes - The closure of the Duo Galleria treatment center in 2023 was due to lease expiration and a shortage of doctors within the group[14]. - The online portal for telemedicine and education services has been trialed but is currently paused for backend software improvements, with plans to relaunch in late 2024[14]. - The group operates five DTAP treatment centers located in Robertson, Novena, Holland Village, Kovan, and Paragon[16]. - The group anticipates facing pressures from global inflation leading to increased operating costs and heightened competition from online healthcare service providers[21]. - Other operating expenses rose by 24.8% to approximately SGD 2.57 million in the current year, primarily due to higher-than-expected marketing expenses[33]. - The group’s total employee count, including part-time staff, was 37 in 2023, down from 39 in 2022[30]. - The company has spent approximately SGD 299,000 to establish a new online business branch for DTAP, with the platform expected to launch around May 2024[66][71]. - SGD 424,000 was utilized to explore new opportunities for vertical expansion, including the establishment of a dedicated medical treatment center[71]. - The company plans to acquire equity in a potential enterprise, with SGD 500,000 allocated for this purpose, expected to be utilized in the second half of FY2025[67]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and regularly reviews its governance practices[138]. - The company has complied with all relevant laws and regulations affecting its business operations during the year[143]. - The company has adopted and complied with all applicable corporate governance codes as per the GEM Listing Rules for the year ending December 31, 2023[153]. - The board consists of four directors, with independent non-executive directors making up over 50% of the board members as of December 31, 2023[158]. - All directors confirmed full compliance with the trading standards set forth in the GEM Listing Rules for the year ending December 31, 2023[154]. - The board held a total of four meetings during the year, with all directors actively participating in committee meetings and shareholder meetings[164]. - The company has ensured that all directors received formal training upon their initial appointment to understand their responsibilities and the company's operations[162]. - Independent non-executive directors contributed significantly to the board by providing rich operational and financial expertise[159]. - The company has established a mechanism for continuous professional development for all directors, encouraging participation in relevant training courses[162]. - The board is responsible for overseeing the business management and overall performance of the group, ensuring necessary financial and human resources support[155]. - The company has maintained a balanced composition of executive and non-executive directors to ensure independent judgment[158]. - The company has taken out appropriate insurance for directors to cover any liabilities arising from their duties[160]. - The board has adopted a diversity policy and aims to appoint at least one female director by December 31, 2024, in compliance with GEM Listing Rule 17.104[166]. - The audit committee is responsible for reviewing the financial statements and ensuring the independence of external auditors[171]. - The nomination committee is tasked with evaluating candidates for board positions and ensuring compliance with governance policies[174]. - The company has a policy for the rotation and re-election of directors, requiring one-third of the board to retire at the annual general meeting[187]. Risk Management - The company has implemented policies and procedures for risk management and internal controls, with the board responsible for monitoring their effectiveness[195]. - The board confirmed that the risk management and internal control systems are designed to manage risks rather than eliminate them, providing reasonable assurance against material misstatements or losses[195]. - The company has appointed a compliance officer since September 30, 2020, to oversee compliance matters[200]. - The board is aware of its responsibility to prepare the annual report and audited consolidated financial statements to reflect the group's condition fairly[193]. - There are no significant uncertainties that may cast doubt on the company's ability to continue as a going concern[194]. Shareholder Information - The company confirms it maintains a sufficient public float, with at least 25% of its issued shares held by the public as of the report date[140]. - The total remuneration for external auditors for the year ending December 31, 2023, amounted to SGD 158,600, with SGD 148,000 for audit services and SGD 10,600 for non-audit services[191]. - The company has not entered into any stock-linked agreements during the fiscal year ending December 31, 2023[142]. - The company has not disclosed any tax reliefs related to shareholder equity holdings[146]. - The company will ensure that no director participates in determining their own remuneration, maintaining independence in the process[185].

Financial Performance - The group recorded revenue of approximately SGD 7.9 million for the nine months ended September 30, 2023, an increase of about 18.1% compared to SGD 6.5 million for the same period last year [5]. - Gross profit for the period was approximately SGD 5.2 million, up about 22.5% from SGD 4.2 million in the previous year, primarily due to the lifting of Covid-19 restrictions in Singapore [6]. - The group reported a lower net loss of approximately SGD 0.4 million for the period, compared to a net loss of SGD 1.2 million in the same period last year [6]. - The group reported a comprehensive loss of approximately SGD 424.5 million for the nine months ended September 30, 2023, compared to a loss of SGD 1.18 million in the same period last year [11]. - For the nine months ended September 30, 2023, the group's revenue increased by approximately SGD 1.2 million or 18.1% to approximately SGD 7.9 million compared to the same period in 2022 [26]. - For the three months ended September 30, 2023, the group's revenue increased by approximately SGD 0.2 million or 7.8% to approximately SGD 2.5 million compared to the same period in 2022 [29]. - The group reported a basic loss per share of SGD (0.03) for the three months ended September 30, 2023, compared to a profit of SGD 0.01 in the same period of 2022 [22]. - The group incurred a loss attributable to owners of the company of SGD (158,641) for the three months ended September 30, 2023, compared to a profit of SGD 32,350 in the same period of 2022 [22]. Operational Insights - The group experienced a significant increase in patient numbers as foreign patients returned to seek timely and quality medical care in Singapore [6]. - Revenue from treatment services, medical examination services, and consultation services for the nine months ended September 30, 2023, were approximately SGD 4.6 million, SGD 2.0 million, and SGD 1.0 million, accounting for approximately 58.7%, 24.8%, and 13.3% of total revenue, respectively [26]. - The group anticipates that the demand for its clinic services may return to pre-pandemic levels due to the lifting of Covid-19 related restrictions and the relaxation of global travel limitations [29]. - The group operates five DTAP clinics located in Robertson, Novena, Holland Village, Kovan, and Paragon as of the report date [27]. Financial Position - The group’s total equity as of September 30, 2023, was approximately SGD 13.69 million, down from SGD 15.59 million at the beginning of the year [11]. - As of September 30, 2023, the group's cash and cash equivalents were approximately SGD 11 million, up from SGD 10 million as of December 31, 2022 [37]. - The capital debt ratio as of September 30, 2023, was approximately 9.5%, an increase from 5.7% as of December 31, 2022 [38]. - The group had no significant contingent liabilities as of September 30, 2023 [42]. Strategic Outlook - The group plans to expand its business model through strategic partnerships and regional outreach to provide more accessible healthcare services [27]. - The company remains cautiously optimistic about the business environment despite signs of improvement, due to potential negative impacts from various external factors [6]. - The group maintains a cautiously optimistic outlook amid geopolitical uncertainties and inflation threats, focusing on enhancing business revenue and profitability [27]. Corporate Governance - The board has resolved not to declare any dividends for the period, consistent with the previous year [7]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and found them compliant with applicable accounting standards [64]. - No directors or controlling shareholders have interests in any competing businesses during the period [62]. - The company has no outstanding stock options as of September 30, 2023, indicating no dilution of shares from options [56]. - The company did not redeem any of its listed securities during the period [63]. - The company has not purchased or sold any of its listed securities during the reporting period [63]. - There were no significant investments or acquisitions during the three-month period ending September 30, 2023 [41]. - The group has not recognized any overseas profits tax for entities registered in the British Virgin Islands or Cayman Islands due to tax exemptions [19].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 Republic Healthcare Limited （於開曼群島註冊成立之有限公司） （股份代號：8357） 截至2023年9月30日止九個月之 第三季度業績公告 Republic Healthcare Limited（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」）會公佈 本集團截至2023年9月30日止九個月之未經審核簡明綜合財務業績。本公告遵照聯交所 GEM證券上市規則（分別為「GEM」及「GEM上市規則」）有關季度業績初步公告隨附資料的 相關規定，載列本公司2023年第三季度報告（「2023年第三季度報告」）的全文。2023年第三 季度報告之印刷本，將於適當時候按照GEM上市規則規定的方式寄發予本公司股東，並將 於聯交所網站www.hkexnews.hk及本公司網站republichealthcare.asia可供查閱。 代表 Republic Healthcare L ...

Financial Performance - The group recorded revenue of approximately SGD 5.4 million for the six months ended June 30, 2023, an increase of about 28.6% compared to SGD 4.2 million in the same period last year[10]. - Gross profit for the period was approximately SGD 3.5 million, up about 29.6% from SGD 2.7 million in the previous year[11]. - The group reported a net loss of approximately SGD 0.3 million after tax, significantly improved from a net loss of SGD 1.2 million in the same period last year[12]. - Revenue for the three months ended June 30, 2023, was SGD 2,508,791, representing a 18.8% increase from SGD 2,110,668 in the same period of 2022[15]. - Total revenue for the six months ended June 30, 2023, reached SGD 5,403,458, up 29.7% from SGD 4,166,600 in the prior year[15]. - The net loss for the three months ended June 30, 2023, was SGD 156,402, a significant improvement compared to a net loss of SGD 506,959 in the same period of 2022[15]. - The net loss for the six months ended June 30, 2023, was SGD 280,860, compared to a net loss of SGD 992,700 in the same period of 2022[15]. - The company reported a basic loss per share of SGD (0.03) for the three months ended June 30, 2023, compared to SGD (0.10) for the same period in 2022[49]. - For the six months ended June 30, 2023, the basic loss per share was SGD (0.04), improving from SGD (0.20) in the same period of 2022[49]. Revenue Drivers - The increase in revenue was attributed to the lifting of COVID-19 restrictions in Singapore and the region, leading to a rise in patient visits[11]. - Revenue from consultation services, medical examination services, and treatment services accounted for approximately SGD 0.6 million, SGD 1.3 million, and SGD 3.1 million, representing 12.5%, 24.6%, and 57.9% of total revenue, respectively[75]. Cash Flow and Liquidity - Cash and cash equivalents increased to SGD 11,535,371 as of June 30, 2023, from SGD 10,834,550 at the end of 2022[18]. - Operating cash flow for the six months ended June 30, 2023, was a net outflow of SGD 166,939, compared to a net outflow of SGD 31,294 in the same period of 2022[21]. - The company has no external borrowings and is not subject to any externally imposed capital requirements[39]. - The company maintains a prudent cash management policy to ensure strong liquidity for future growth opportunities[93]. Assets and Liabilities - Total assets as of June 30, 2023, were SGD 16,461,682, slightly up from SGD 16,416,343 at the end of 2022[17]. - The company’s equity attributable to owners decreased to SGD 13,856,773 as of June 30, 2023, from SGD 14,117,094 at the end of 2022[18]. - The total amount of trade payables as of June 30, 2023, was SGD 536,313, slightly up from SGD 518,449 as of December 31, 2022[65]. - The group’s lease liabilities increased to SGD 960,249 as of June 30, 2023, compared to SGD 810,473 as of December 31, 2022[53]. Business Operations - The company operates primarily in Singapore, focusing on healthcare services and management consulting, with a recent cessation of its pepper trading business as of May 2023[23]. - The company operates six DTAP clinics and has launched a new online healthcare platform branded "Quinn" to expand its service offerings[78]. - The company has decided to cease operations of its pepper trading business due to limited profitability over the past 12 months[47]. Strategic Outlook - The group remains cautiously optimistic about the business environment despite external factors such as tightening monetary policies and geopolitical tensions impacting global economic growth[12]. - The company maintains a cautiously optimistic outlook despite geopolitical and inflationary uncertainties, aiming to enhance overall business revenue and profitability[76]. - The company continues to explore strategic partnerships and acquisitions to expand its business model into other regions[76]. Accounting and Compliance - The financial statements are prepared in accordance with International Financial Reporting Standards and GEM listing rules, with no significant changes in accounting policies from the previous year[24]. - The company has adopted all applicable International Financial Reporting Standards effective from January 1, 2023, with no significant impact on reported amounts[24]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited condensed consolidated financial statements and found them compliant with applicable accounting standards[125]. Shareholder Information - As of June 30, 2023, Dr. Chen holds 350,000,000 shares, representing 56.09% of the total issued shares of 624,000,000[116]. - Cher Sen Holdings Limited, wholly owned by Dr. Chen, holds 350,000,000 shares, equating to 56.09% ownership[117]. - Dr. Chen is the beneficial owner of 100% of Cher Sen's shares, which is a direct shareholder of the company[118]. - No other entities, apart from those disclosed, hold any interests in the company's shares as of June 30, 2023[121].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 Republic Healthcare Limited （於開曼群島註冊成立之有限公司） （股份代號：8357） 截至2023年6月30日止六個月之中期業績公告 Republic Healthcare Limited（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」）會茲公 佈本集團截至2023年6月30日止六個月之未經審核簡明綜合財務業績。本公告遵照聯交所 GEM證券上市規則（分別為「GEM」及「GEM上市規則」）有關中期業績初步公告隨附資料的 相關規定，載列本公司2023年中期報告（「2023年中期報告」）的全文。2023年中期報告之印 刷本，將於適當時候按照GEM上市規則規定的方式寄發予本公司股東，並將於聯交所網站 www.hkexnews.hk及本公司網站republichealthcare.asia可供查閱。 代表 Republic Healthcare Limited 主 ...

Financial Performance - The group recorded revenue of SGD 2.89 million for the three months ended March 31, 2023, an increase of approximately 27.8% compared to SGD 2.06 million in the same period last year[5]. - Gross profit for the period was SGD 1.8 million, up approximately 33.8% from SGD 1.3 million in the previous year[6]. - The group reported a post-tax net loss of approximately SGD 0.1 million, a significant reduction from a net loss of approximately SGD 0.7 million in the same period last year[6]. - The group’s total comprehensive loss for the period attributable to owners was SGD 104,656, compared to a loss of SGD 659,403 in the previous year[10]. - Revenue for the first quarter of 2023 increased by approximately SGD 0.57 million or 27.8% to about SGD 2.89 million compared to SGD 2.06 million in the same period last year[34]. - Treatment services revenue was SGD 1,568,840, medical examination services revenue was SGD 709,705, and consultation services revenue was SGD 348,069, contributing approximately 54.2%, 24.5%, and 12.0% to total revenue respectively[19]. - Gross profit increased by approximately SGD 0.45 million to about SGD 1.8 million, while gross margin decreased from approximately 64.8% to 62.2% due to lower profit margins from pepper trading[35]. - The net cash generated from operating activities was approximately -SGD 0.01 million for the period, an improvement from -SGD 0.7 million for the previous year[46]. Business Strategy and Operations - The decrease in net loss was primarily due to the sale of two businesses in February 2022, allowing the group to focus on developing other existing business opportunities[6]. - Management is optimistic about continued revenue growth, especially with the resumption of international travel and the lifting of COVID-19 border measures[6]. - The company plans to enhance service quality and expand its online health services to increase brand influence and explore new business opportunities[30]. - The acquisition of three entities for SGD 286,594 is part of the company's strategy to develop healthcare-related education business, expected to be completed by April 30, 2023[32]. - The group operates medical treatment centers and provides management consulting services, alongside pepper trading and education-related businesses[14]. Financial Position and Equity - The group’s total equity attributable to owners as of March 31, 2023, was SGD 14.01 million, reflecting a decrease from the previous year due to accumulated losses[12]. - As of March 31, 2023, the group's cash and cash equivalents were approximately SGD 10.7 million, slightly down from SGD 10.8 million as of December 31, 2022, with no bank borrowings reported[45]. - The capital debt ratio as of March 31, 2023, was 4.93%, a decrease from 5.7% as of December 31, 2022, with lease liabilities amounting to approximately SGD 0.69 million[46]. - The employee count increased to 43 as of March 31, 2023, from 39 as of December 31, 2022, with all employees being full-time[44]. Dividends and Shareholder Information - The board has resolved not to declare any dividends for the period, consistent with the previous year[7]. - As of March 31, 2023, Dr. Chen holds 350,000,000 shares, representing 56.09% of the total issued shares of 624,000,000[64]. - Cher Sen Holdings Limited, wholly owned by Dr. Chen, is the direct shareholder with 350,000,000 shares, accounting for 56.09%[69]. - Dr. Chen is the beneficial owner of 100% of Cher Sen's shares, which indicates a strong control over the company[66]. - No other directors or executives hold any interests in the company's shares or related securities as of March 31, 2023[65]. Compliance and Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the financial statements and confirmed compliance with applicable accounting standards[73]. - The company has established an audit committee to oversee financial reporting and risk management processes[73]. - There are no reported interests or conflicts of interest from directors or controlling shareholders in competing businesses[71]. - The financial disclosures have been deemed sufficient and compliant with GEM listing rules and other legal requirements[73].